These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20509715)

  • 1. Dapagliflozin: BMS 512148; BMS-512148.
    Drugs R D; 2010; 10(1):47-54. PubMed ID: 20509715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin for the treatment of type 2 diabetes.
    Anderson SL; Marrs JC
    Ann Pharmacother; 2012 Apr; 46(4):590-8. PubMed ID: 22433611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecule of the month. Dapagliflozin.
    Drug News Perspect; 2007 Dec; 20(10):645. PubMed ID: 18301798
    [No Abstract]   [Full Text] [Related]  

  • 6. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
    Mauricio D
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
    Kilov G; Leow S; Thomas M
    Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
    Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
    Chao EC
    Discov Med; 2011 Mar; 11(58):255-63. PubMed ID: 21447284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin, an SGLT2 inhibitor, for diabetes.
    Hanefeld M; Forst T
    Lancet; 2010 Jun; 375(9733):2196-8. PubMed ID: 20609956
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].
    Zhang WB; Gong N; Wang YX
    Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):453-6. PubMed ID: 21416966
    [No Abstract]   [Full Text] [Related]  

  • 15. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
    Shaikh S; Rizvi SM; Shakil S; Riyaz S; Biswas D; Jahan R
    Biotechnol Appl Biochem; 2016; 63(1):145-50. PubMed ID: 25402624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
    Rizos EC; Elisaf MS
    Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin for the treatment of type 2 diabetes.
    Brooks AM; Thacker SM
    Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
    Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
    Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
    Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
    Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.